Voyager Therapeutics Inc (VYGR) Rating Increased to Hold at Zacks Investment Research
Voyager Therapeutics Inc (NASDAQ:VYGR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other equities analysts have also commented on the stock. Nomura began coverage on shares of Voyager Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Friday, January 20th. Instinet began coverage on shares of Voyager Therapeutics in a research note on Wednesday, March 1st. They issued a “buy” rating and a $31.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Voyager Therapeutics in a research note on Friday, January 20th. Finally, TheStreet cut shares of Voyager Therapeutics from a “c-” rating to a “d+” rating in a research note on Friday, April 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $27.50.
Voyager Therapeutics (NASDAQ:VYGR) opened at 9.25 on Wednesday. The firm’s market cap is $248.38 million. Voyager Therapeutics has a one year low of $8.48 and a one year high of $18.25. The stock’s 50 day moving average is $10.84 and its 200-day moving average is $12.14.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.11. The company had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.70 million. Voyager Therapeutics had a negative return on equity of 20.58% and a negative net margin of 195.31%. On average, equities research analysts expect that Voyager Therapeutics will post ($2.58) earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in VYGR. Aberdeen Asset Management PLC UK acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $177,000. Russell Investments Group Ltd. acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $194,000. Teachers Advisors LLC boosted its stake in shares of Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after buying an additional 1,847 shares during the period. Bessemer Group Inc. acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $278,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Voyager Therapeutics by 3.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock worth $383,000 after buying an additional 1,026 shares during the period. 39.95% of the stock is owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related stocks with our FREE daily email newsletter.